Aardvark Therapeutics, Inc.
AARDCIK 0001774857 · Every Form 4 filed by insiders at this issuer. See financials →
Annual report (10-K)
Latest 10-K filed Mar 23, 2026. Sentiment + YoY language diff vs prior year. Read sections →
Signal:NeutralFull-doc fallback
Full filing:tone -0.0166Δ-0.000789% similar+535/-571 ¶
Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.
Recent 8-K announcements
Per-item disclosure feed. Item 2.02 is the earnings release.
Top insiders
Most active reporters at Aardvark Therapeutics, Inc.
| Name | Roles | Filings |
|---|---|---|
| Baynes Roy D. | Director | 1 |
| Chen Bihua | - | 1 |
| Cormorant Asset Management, LP | - | 1 |
| Cui Xiangmin | 10% Owner | 1 |
| Decheng Capital Global Healthcare Fund (Master), LP | 10% Owner | 1 |
Top performers
Insiders ranked by realized 90-day signed return on their open-market trades at Aardvark Therapeutics, Inc.. Minimum 3 scored trades. Returns are signed - a sale followed by a rally counts against the insider.
| # | Insider | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|---|
| 1 | Lee Tien-Li | 7 | 71% | +32.1% | +45.4% | +81.7% | -66.7% |
| 2 | Sun Nelson | 3 | 33% | -7.9% | -31.7% | +74.7% | -66.7% |
All filings
25 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|